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Introduction: Multiple environmental and genetic factors are involved with the development of basal cell
carcinomas (BCC), as well as with breast cancers. Tumor initiation and progression are often associated with
genomic instability such as aneuploidies, and gains or losses of large chromosomal segments, known as copy
number alterations (CNAs). CNAs have been successfully detected using the microarray comparative genomic
hybridization technique (array-CGH) at high resolution. Data thus obtained are useful to identify specific genomic
aberrations, to classify tumor stages, and to stratify subgroups of patients with different prognosis and clinical
behaviors.
Case description: Clinical study of a 66-year-old white female identified two primary tumors, a ductal invasive
grade-II carcinoma of the breast, and one nodular BCC. Germline and tumor genomic survey utilized the 180 K
array-CGH analysis to investigate chromosomal alterations.
Discussion and evaluation: Several chromosomal anomalies were detected in the breast tumor genome,
including focal ~422 Kb 13q13.3 microdeletion. In the BCC, amplification of a chromosome 6 spanning the
centromere region between the cytobands 6p23 and 6q12 was identified. Several 6p amplified genes correspond
to families of histone and human leukocyte antigen genes, whereas some of the CNAs found in the breast tumor
are uncommon. No germline CNA was detected in the normal skin of the patient at this technical resolution.
Conclusion: CNAs found in the two different tumors of the patient constitute independent events arisen in the
somatic lineage. Relevant genes to both carcinogenesis and progression are to be affected by these CNAs.
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Cancer establishment depends on multistep alterations of
the genome including gene mutations, deletions or inser-
tions, and epigenetics aberrations, leading to decreased
apoptosis, increased cell proliferation, angiogenesis, inva-
sion and metastasis. The tumor progression is often asso-
ciated with gross genomic instability such as aneuploidies,
and gains and losses of chromosomal regions.
Copy number alterations (CNAs) of DNA segments
have been successfully detected by the array-CGH tech-
nique at high resolutions allowing the simultaneous in-
vestigations of thousands of genes in the entire genome.
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suppressor genes, respectively.Clinical and molecular aspects
Although BCC presumably develops from epidermal
stem cells of the outer root sheet of the hair follicle, the
precise origin of BCC is still unknown. Apart from the
environmental exposure and immunosuppressive ther-
apy, people with a fair skin type-I complexion including
red or blonde hair, light colored eyes, freckling, and
those with a history of intermittent sun exposure, espe-
cially ultraviolet B radiation and severe sunburn during
childhood, are at highest risk (Göppner and Leverkus
2011).
The estimated number of new-cases of non-melanoma
skin cancer in Brazil was approximately 160,000 in 2012,
the risk being 75 and 84 new cases per 100,000 for malesan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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according to specific regions and population ethnical
composition, and are particularly high in the Central,
South and Southern Brazilian regions (INCA 2012).
BCCs are classified into five types: nodular-ulcerative,
pigmented, sclerodeiform or fibrosing, superficial and
fibroepithelioma. The nodular ulcerative is the most
common form, usually isolated and affecting mainly the
head and neck (Chinem and Miot 2011). Less than 1%
BCC metastasizes, mostly to lymph nodes, lungs and
bones (Bader and Scarborough 2000). Treatment op-
tions are focused on local control, including surgical
techniques as curettage and electrodessication, cryosur-
gery, surgical excision, and Mohs micrographic surgery.
Nonsurgical approaches include radiotherapy, topical in-
jection therapy, and photodynamic therapy (Rubin et al.
2005).
Mutations in genes associated with the sonic hedgehog
(SHH) signaling pathway, as well as defects in repair
genes or up-regulation of transcription factors have been
implied in the development of BCC (Iwasaki et al. 2013).
Also, several genes involved in oxidative phosphorylation
and energy metabolism are up-regulated in both melan-
oma and BCC (Xu et al. 2012).
Germline deletions affecting the PTCH1 gene is respon-
sible for the Gorlin syndrome phenotype also known as
Nevoid Basal Cell Carcinoma Syndrome (NBCCS). A Gor-
lin Syndrome patient bearing 46,XY and a de novo del(9)
(q22.3q31.3) was reported (Chen et al. 2006). This deletion
that was detected on array-CGH analysis besides other
techniques, led to the heterozygous loss of the PTCH1
gene (9q22.3). Another case also showed deletion on the
9q arm [46,XX,del(9)(q22.1q22.32)], including the PTCH1
and ROR2 genes: A 12 year old girl exhibited several
NBCCS features but no tumors yet, since BCCs usually
manifest after puberty (Nowakowska et al. 2007). Simi-
larly, a 46,XY patient who showed abnormal non-Gorlin
features in early age, and exhibited a de novo deletion in
this same region encompassing the PTCH1 gene was de-
scribed (de Ravel et al. 2009). Recent study on basaloid
squamous cell carcinomas (SCC) and carcinosarcoma,
which are set apart from classical SCC, detected CNAs
gains in chromosomes 2p, 7q, 11q, and losses at 13q31ter
(Schaefer et al. 2011).
Regarding breast cancer, about one million new cases
per year are referred worldwide, from which 35% patients
will eventually die. In Brazil, the estimative of new breast
cancer cases in 2012 was 52,680 and 12,705 deaths (INCA
2012). Breast cancer is a heterogeneous disease with histo-
logical differences within tumors and between patients.
The cancer development in the normal mammary gland
depends on stem cells, neighboring cells, including fat
cells and fibroblasts that play distinct roles through
specific signaling pathways (Ercan et al. 2011).Several factors have been associated with an increased
risk of breast cancer, such as family history, nulliparity,
early menarche, advanced age, and a personal history of
in situ or invasive breast cancer. Of all women with
breast cancer, 5 to 10% may have a germline mutation of
the genes BRCA1 and BRCA2 (Blackwood and Weber
1998). The estimated lifetime risk of developing breast
cancer for women with BRCA1 and BRCA2 mutations is
40% to 85% (Frank et al. 1998).
The treatment of breast cancer includes surgery, radi-
ation therapy, chemotherapy, and hormone therapy. The
prognosis and selection of therapy may be influenced by
clinical and pathological features, such as age, menopausal
status, stage disease, histological and nuclear grade, hor-
mone receptor status, over expression of human epider-
mal growth factor 2 (HER2/neu) and proliferative capacity
of the tumor (Simpson et al. 2000). Molecular profiling
has led to the classification of breast cancer into five
distinct subtypes: basal-like, HER2+, normal, luminal A
and luminal B (Perou et al. 2000; Sørlie et al. 2001). Patho-
logical and molecular markers as well as gene expression
profiles are useful to estimate the risk of breast cancer
recurrence after surgery.
The array-CGH technology has been used to iden-
tify subgroups of patients with different prognosis and
clinical behaviors, as well as to discover susceptibility
genes, oncogenes and tumor suppressor genes. Dis-
tinct array-CGH profiles were described for ductal
and lobular, tubular/tubulo lobular, medullary, micro-
papillary and secretory breast carcinomas. Loss of 16q
has been associated with good prognosis, being more
common in lobular than ductal carcinomas. Chromo-
some 8p11-12 (about 10 Mb) is a gene-dense region that
has been implicated in various tumor types. BRCA1-
mutated, BRCA2-mutated, and sporadic breast tumor
classes presented loss of chromosome arm 8p, and gain
of arm 8q (Didraga et al. 2011). Amplification of 8p11-12,
11q13-14, and 20q13 was correlated with poor prognosis
(Climent et al. 2007).
Twenty-three female patients bearing breast cancer, eleven
of them with more than one primary tumor type, were
studied (Silva et al. 2012). Four out of the eleven breast
cancer patients beard a skin cancer. The BRCA1, BRCA2
and TP53 genes studied by the MLPA technique showed
no CNAs in the germline (blood DNA), except for a single
breast cancer patient. A micro deletion flanked by repeti-
tive Alu sequences in the BRCA1 gene at 17q21.31 was
detected by array-CGH profile and sequencing.
In the present report, a BCC and a breast carcin-
oma, developed simultaneously in two different areas
of the skin of a patient, were clinically and genetically
characterized. The array-CGH analysis detected differ-
ent somatic CNAs in both tumors, but not in the normal
tissue.
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The clinical diagnosis and history of the 66 year old
female patient comprise an ulcerative lesion on the
left dorsum that evolved within about 3 years. Another
ulcerative lesion developed on the right breast within
about 2 years. The menarche and menopause were
attained when the patient was 13 and 55 year old, re-
spectively. Hormonal replacement was carried out for
more than 10 years. The patient’s sister died due to
cutaneous melanoma.
Method
Genomic DNA was isolated from fresh frozen samples of
the breast cancer and the BCC, labeled with fluorescence
and cohybridized with normal reference DNA. Microarray-
Comparative Genome Hybridization analysis was per-
formed as previously described (Krepischi et al. 2012) using
a whole-genome 180 K platform (Agilent Technologies,
Santa Clara, California, USA), containing about 180,000 oli-
gonucleotides throughout the human genome, according to
the manufacturer’s instructions. A gain or loss in copy
number was considered when the log2 ratio of the Cy3/Cy5
intensities of a given genomic segment was >0.3 or <−0.3,
respectively. A commercially available pool of female DNAs
(Promega, Madison, WI, USA) was used as the reference
DNA in the array-CGH experiments.
Results and discussion
Clinical analysis
The mammography revealed a speculated nodule with
high radio sensitivity, associated to skin retraction, at the
upper internal right breast. The echography showed a
2.6 cm tumor that reached the skin and pectoral muscle.
Adjacent to this nodule, another one was identified
within 1.4 cm from the former, which exhibited similar
characteristics and measured 2.0 cm, attaining also the
pectoral muscle.Figure 1 The ulcerative lesion developed on the left dorsum was furtBiopsies revealed an adenoid BCC lesion at the left
dorsum (Figure 1); and a ductal invasor carcinoma
(histological degree II; accentuated formation of tubules;
moderate mitotic index; macroscopic metastasis in
lymph nodes; and angio lymphatic invasion) at the right
breast that infiltrated the skin, compatible with a pri-
mary breast cancer (Figure 2). The patient was submit-
ted to neoadjuvant chemotherapy protocol AC and both
lesions were surgically resected. Further, adjuvant
radiotherapy and electrons beam were used at the left
dorsum. The patient started the adjuvant treatment for
the breast carcinoma with hormonal blocking via oral
anastrosole 1 mg/day, and till now has no evidence of
neoplasia activity.
Molecular array-CGH profile in BCC
A genomic gain in the BCC sample affected about 53
Mb of the chromosome 6 mapped to 6p23–q12, at chr6:
14838756–68055170 (Genome Build Hg18) (Figure 3;
Additional file 1: Figure S1). The affected region exhibit
distinct levels of gain, one of them compatible with a
moderate amplification. Many genes are found in this re-
gion (Additional file 2: Table S1), some of them already
associated with cancer, such as the tumor suppressor
gene CDKN1A, at 6p21.2.
The amplifications found at 6p21.3 attained particularly
the histone cluster 1 H1d gene family (HIST1H1D) re-
sponsible for chromosome structure and function, and the
great number of genes encoding several classes of the
major histocompatibility complex antigens (HLA). There
are 173 genes at the end of the 6p23-p11 which are
repeated in the 6p21.2-p11.2. This pericentromeric gain in
the chromosome 6 suggests that the gain/amplification
may be carried by the tumor genome as a ring chromo-
some containing the affected sequence.
The specific gene PTCH1 was also investigated, but no
alterations were found at the resolution used (~4 Kb).her identified in the biopsy as an adenoid BCC.
Figure 2 Ductal invasion carcinoma at the right breast is compatible with a primary breast cancer. The tumor with histological degree II,
showed accentuated formation of tubules, moderate mitotic index, macroscopic metastasis in lymph nodes, angio lymphatic invasion and
infiltration of the skin.
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cancers, array-CGH studies have also shown chromosome
6 gains in SCC (Li et al. 2010; Li et al. 2012), melanoma
(Pirker et al. 2010) and Merckel carcinoma (Paulson et al.
2009). Small supernumerary marker chromosomes and
also ring chromosomes have been found in several in-
stances as derived from chromosome 6 (Huang et al. 2012;
Guilherme et al. 2012). Deletions at the end of both arms
of one allele 6 are often involved in this rare de novo event.
The presence of a large amount of euchromatin extending
beyond distal 6p12.1 and proximal 6q12 (ring chromo-
some) has been associated with an abnormal phenotype on
a girl 46,XX,r(6)(p25q27) (Ciocca et al. 2013).
Molecular array-CGH profile in breast carcinoma
Contrarily to the genome alterations observed in the BCC,
which were restricted to 6p, a great number of CNAs
affecting several chromosomes (Figure 3; Additional file 3:
Figure S2) and genes (Additional file 2: Table S1) were
identified in the breast carcinoma. The alterations include
a total loss of whole chromosome 22, and partial aneu-
ploidy of large chromosomal regions at 4p, 4q, 6q, and
17p, some exhibiting a complex genomic pattern. A sub-
microscopic focal deletion ~422 Kb was found at 13q13.3
and affected only three genes: LINC00547 (long intergenic
non-coding RNA 547); TRPC4 (transient receptor poten-
tial cation channel, subfamily C, member 4); and POSTN.
The POSTN gene encodes the osteoblast specific factor
periostin that is associated with cellular adhesion; it is
expressed in normal breast tissue, and is up regulated in
breast cancer (Zhang et al. 2010).
Specific BRCA1/BRCA2 genes were also investigated,
but no alterations were detected.
Breast cancer tissues often show alterations in chromo-
somes 13q and/or 22 (Climent et al. 2007; Li et al. 2009;
Li et al. 2010; Didraga et al. 2011). Among the array-CGHimbalances detected in 75% invasive ductal carcinoma
breast cancer samples, there was chromosomal loss of 13q
in 3 cases with lymph node metastasis, besides chromo-
somal gains of +1q, +17q, and +8q (Ghaffari et al. 2008).
Loss of the 13q14 region was also detected in benign
mammary and vaginal myofibroblastomas (Magro et al.
2012). Deletions detected at 13q and 14q were proposed
as hallmarks of BRCA2–mutant tumors (Rouault et al.
2012). Besides being the BRCA2 gene locus (13q12), the
13q region harbors the tumor suppressor gene RB1 and
the gene encoding the transcription factor FOX01.
The 17p arm harbors among several other genes, the
TP53 tumor suppressor gene and HIC1 (zinc-finger pro-
tein hypermethylated in cancer 1) gene, at 17p13.1 and
17p13.3, respectively, that were deleted in the present
breast tumor sample.
Losses in chromosome 22 ranged from the whole 22q
to the gain of just a few hundred kb in 11% of breast can-
cers, besides several imbalances present in other samples
(Benetkiewicz et al. 2006). A candidate tumor suppressor
gene MYO18B was located in this region (Yanaihara et al.
2004). One subgroup of breast tumors without known
BRCA1 and BRCA2 mutations showed specific gain of the
22 chromosome (Didraga et al. 2011). Similarly to the
findings in the present study, loss of 4q, 6q, and 13q were
detected.
No deletions or duplications >300 kb were identified
in the normal tissue of the patient. Specific investigation
concerning BRCA1 (at ~20 Kb resolution), BRCA2 and
PTCH1 (at ~4 Kb resolution) genes did not detect
submicroscopic duplications or deletions in the control
sample.
Conclusion
The CNAs occurred independently in both BCC and
breast cancer and none of them was present in the normal
Figure 3 CNAs in whole BCC and breast cancer genomes are shown. a. The single amplification found was located at chromosome 6p of
the BCC sample. b. Several chromosomes were attained by deletions in the breast carcinoma.
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in the BCC sample (6p21.3 gain) contains the histone
cluster 1 H1d gene family, whose super dosage may have
affected the modeling of local chromatin with wide conse-
quences on deregulation of genes activity. In addition, the
duplication of great number of genes encoding several
classes of the MHC antigens may have contributed to the
BCC genesis. Regarding the complex genomic pattern of
the breast tumor, haplo insufficiency of suppressor genescould play a role in the development and progression of
this disease.
Consent
This study was approved by the institutional ethics com-
mittee of the Moinhos de Vento Hospital, Porto Alegre,
RS, Brazil (Protocol number 374.454, August 21st. 2013),
and the patient has given an informed consent for the re-
search and publication of this study and any accompanying
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biopsies from normal breast tissue, breast tumor and
BCC.
Additional files
Additional file 1: Figure S1. Array-CGH profile of the chromosome 6
from the BCC genome (Agilent 180 K microarray; Genomic Workbench
software). The Y axis corresponds to log2 values of the ratios between
sample (Cy3) and reference DNA (Cy5). A pericentromeric gain at
6p23–q12 can be easily visualized in the chromosome 6 ideogram
(blue bars), ranging from chr6: 14838756–68055170 (Genome Build
Hg18). This pericentromeric pattern of genomic gain suggested a
rearrangement structure of a ring chromosome.
Additional file 2: Table S1. Genes involved in DNA loss in breast
cancer and gain in BCC samples from the patient studied. Deletion of
some gene families could be particularly involved in the development of
the breast cancer through haplo insuficiency, as zinc fingers transcription
factors (ZNF), ubiquitin specific peptidases (USP), breast cancer 1A-complex
subunit Abraxas (FAM), besides other important genes, as CDKN2AIP, CASP3,
TP53, BCL2L13, BID, NFKB1, and TIMP3. In the BCC, a segment of genes
present in the 6p23-p11 is repeated at the 6p21.2-p11.2. Some gene families
particularly involved in the amplification, as histones (HIST) and major
histocompatibility antigens (HLA), were identified as well as other
genes located in the affected area, as CDKN1A and VEGFA.
Additional file 3: Figure S2. Array-CGH profiles from the breast cancer
genome showing CNAs (Agilent 180 K microarray; Genomic Workbench
software). The Y axis corresponds to log2 values of the ratios between
sample (Cy3) and reference DNA (Cy5). a. Array-CGH profile of the
chromosome 4: the dark gray bars point to the 4p and 4q genomic
segments that exhibited losses (.jpg 118 K). b. Array-CGH profile of the
chromosome 6: the dark gray bars point to 6q genomic regions that
exhibited losses (.jpg 118 K). c. Array-CGH profile of the chromosome 17:
the dark gray bar indicates a deleted area of 17p (.jpg 111 K). d. Array-CGH
profile of the chromosome 22 showing a whole chromosome aneuploidy
(loss) (.jpg 100 K). e. A focal ~422 kb micro deletion at 13q13.3 is detailed
(shaded dark gray bar); below are indicated the RefSeq genes mapped in
the affected genomic region (.jpg 87 K).
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